DocDollars

Astellas Pharma Inc

Japan · Reporting entity ID 100000010648

Total reported 2019–2025
$44.7M
#189 of 2,960 reporting companies — 0.1% of all reported industry payments
$1.54M in general payments across 355 records, plus $43.2M in research funding across 9,047 records.

How it breaks down

General payments $1,539,962
Research funding $43,159,973

Where this comes from

Figures are from the CMS Open Payments “payments grouped by reporting entity” dataset, queried live. Reporting entities are applicable manufacturers and group purchasing organisations required to report under the Sunshine Act.

Summary

Astellas Pharma Inc reported $44.7M to US doctors and teaching hospitals from 2019 to 2025, ranking #189 of 2,960 reporting companies. 97% of that was research funding and 3% general payments such as consulting, speaking, food and travel. 355 general payment records and 9,047 research records were filed.

Common questions about Astellas Pharma Inc

How much has Astellas Pharma Inc paid US doctors?

Astellas Pharma Inc reported $44,699,935 to US physicians and teaching hospitals across the 2019–2025 Open Payments program years: $1,539,962 in general payments, $43,159,973 in research funding.

How does Astellas Pharma Inc rank among drug and device companies?

It ranks #189 of 2,960 reporting entities by total reported value, about 0.1% of all industry payments in the dataset.

Does a payment from Astellas Pharma Inc mean a doctor did something wrong?

No. Open Payments records transfers of value such as speaking fees, consulting, meals, travel and research funding. The data shows the relationship, not its effect on prescribing or care.